{
    "clinical_study": {
        "@rank": "31619", 
        "arm_group": [
            {
                "arm_group_label": "BIAsp 30", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BHI 30", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics,\n      pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes."
        }, 
        "brief_title": "Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes", 
        "completion_date": {
            "#text": "November 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes for at least 12 months\n\n          -  Treated with a combination of soluble/protracted human insulin in the ratio of 30/70\n             in a twice-daily regimen for at least 6 months\n\n          -  BMI (body mass index) below 39 kg/m^2\n\n          -  HbA1c (glycosylated haemoglobin) below 12%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697618", 
            "org_study_id": "ANA/DCD/046"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BIAsp 30", 
                    "BHI 30"
                ], 
                "description": "Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs", 
                "intervention_name": "biphasic insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "BIAsp 30", 
                    "BHI 30"
                ], 
                "description": "Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs", 
                "intervention_name": "biphasic human insulin 30", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 2, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alphen a/d Rijn", 
                        "country": "Netherlands"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crawley", 
                        "country": "United Kingdom", 
                        "zip": "RH11 9RT"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Single Centre, Two-way Cross-over Trial Comparing the Pharmacokinetics, Pharmacodynamics and Safety of the Biphasic Insulin Aspart 30 and Insulin Mixtard 30/70 After Multiple Dosing With a Twice Daily Dose Regimen in Type 2 Diabetic Patients", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Lisbeth V. Jacobsen", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medicines Evaluation Board, Dutch Health Care Inspectorate", 
                "United Kingdom: Medicines and Healthcare Products Regulatory"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 1998", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the serum insulin curve", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697618"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall shape of the 24 hour serum insulin profile", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Cmax (maximum plasma concentration)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "tmax (time to reach maximum)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Area under the curve following each injections derived from 24 hours serum insulin profiles", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall shape of the 24 hour serum glucose profile", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Serum glucose excursions (EXC)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}